Limits...
The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case-control study.

Dong MJ, Wang LB, Jiang ZN, Jin M, Hu WX, Shen JG - Onco Targets Ther (2014)

Bottom Line: Receiver operating characteristic curve analysis showed that the patients with a histoscore of KLF4 expression >0.18 had a lower pCR rate.Multivariable analysis showed that higher KLF4 expression (odds ratio 0.013; 95% confidence interval 0.013-0.444; P=0.004) was independently correlated with a lower pCR rate after neoadjuvant chemotherapy.KLF4 overexpression was associated with lower pCR in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgical Oncology, Zhejiang University College of Medicine, Hangzhou, People's Republic of China.

ABSTRACT

Background: To identify whether a stem cell biomarker, KLF4, may predict the pathologic tumor response to neoadjuvant chemotherapy for patients with locally advanced breast cancer.

Methods: Twelve locally advanced breast cancer patients who achieved pathologic complete remission (pCR) after neoadjuvant chemotherapy were identified and for each, three non-pCR breast cancer patients - matched for age, clinical tumor-node-metastasis stage, and neoadjuvant chemotherapy cycles - were selected. The relationship between KLF4 expression in the core needle biopsied cancer tissue and patient pCR rate was assessed using univariate and multivariate analysis.

Results: Receiver operating characteristic curve analysis showed that the patients with a histoscore of KLF4 expression >0.18 had a lower pCR rate. Multivariable analysis showed that higher KLF4 expression (odds ratio 0.013; 95% confidence interval 0.013-0.444; P=0.004) was independently correlated with a lower pCR rate after neoadjuvant chemotherapy.

Conclusion: KLF4 overexpression was associated with lower pCR in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy. This study suggests that KLF4 may serve as a predictor for pCR in patients with breast cancer after neoadjuvant chemotherapy.

No MeSH data available.


Related in: MedlinePlus

Immunohistochemical KLF4 staining in normal skin tissue (A, B) and in primary biopsy tissues of human breast cancer (C–F).Notes: Positive control (tissue known to have strong KLF4 expression) at (A) 100× and (B) 400× magnification. High KLF4 expression at (C) 100× and (D) 400× magnification. Low KLF4 expression at (E) 100× and (F) 400× magnification.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4216037&req=5

f2-ott-7-1963: Immunohistochemical KLF4 staining in normal skin tissue (A, B) and in primary biopsy tissues of human breast cancer (C–F).Notes: Positive control (tissue known to have strong KLF4 expression) at (A) 100× and (B) 400× magnification. High KLF4 expression at (C) 100× and (D) 400× magnification. Low KLF4 expression at (E) 100× and (F) 400× magnification.

Mentions: The average KLF4 expression histoscore was 1.02, with a range of 0–2.70 (Figure 2). The pCR group had a lower KLF4 histoscore of 0.24±0.49, and the non-pCR group had a higher KLF4 histoscore of 1.28±0.94 (P=0.001).


The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case-control study.

Dong MJ, Wang LB, Jiang ZN, Jin M, Hu WX, Shen JG - Onco Targets Ther (2014)

Immunohistochemical KLF4 staining in normal skin tissue (A, B) and in primary biopsy tissues of human breast cancer (C–F).Notes: Positive control (tissue known to have strong KLF4 expression) at (A) 100× and (B) 400× magnification. High KLF4 expression at (C) 100× and (D) 400× magnification. Low KLF4 expression at (E) 100× and (F) 400× magnification.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4216037&req=5

f2-ott-7-1963: Immunohistochemical KLF4 staining in normal skin tissue (A, B) and in primary biopsy tissues of human breast cancer (C–F).Notes: Positive control (tissue known to have strong KLF4 expression) at (A) 100× and (B) 400× magnification. High KLF4 expression at (C) 100× and (D) 400× magnification. Low KLF4 expression at (E) 100× and (F) 400× magnification.
Mentions: The average KLF4 expression histoscore was 1.02, with a range of 0–2.70 (Figure 2). The pCR group had a lower KLF4 histoscore of 0.24±0.49, and the non-pCR group had a higher KLF4 histoscore of 1.28±0.94 (P=0.001).

Bottom Line: Receiver operating characteristic curve analysis showed that the patients with a histoscore of KLF4 expression >0.18 had a lower pCR rate.Multivariable analysis showed that higher KLF4 expression (odds ratio 0.013; 95% confidence interval 0.013-0.444; P=0.004) was independently correlated with a lower pCR rate after neoadjuvant chemotherapy.KLF4 overexpression was associated with lower pCR in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgical Oncology, Zhejiang University College of Medicine, Hangzhou, People's Republic of China.

ABSTRACT

Background: To identify whether a stem cell biomarker, KLF4, may predict the pathologic tumor response to neoadjuvant chemotherapy for patients with locally advanced breast cancer.

Methods: Twelve locally advanced breast cancer patients who achieved pathologic complete remission (pCR) after neoadjuvant chemotherapy were identified and for each, three non-pCR breast cancer patients - matched for age, clinical tumor-node-metastasis stage, and neoadjuvant chemotherapy cycles - were selected. The relationship between KLF4 expression in the core needle biopsied cancer tissue and patient pCR rate was assessed using univariate and multivariate analysis.

Results: Receiver operating characteristic curve analysis showed that the patients with a histoscore of KLF4 expression >0.18 had a lower pCR rate. Multivariable analysis showed that higher KLF4 expression (odds ratio 0.013; 95% confidence interval 0.013-0.444; P=0.004) was independently correlated with a lower pCR rate after neoadjuvant chemotherapy.

Conclusion: KLF4 overexpression was associated with lower pCR in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy. This study suggests that KLF4 may serve as a predictor for pCR in patients with breast cancer after neoadjuvant chemotherapy.

No MeSH data available.


Related in: MedlinePlus